Dapagliflozin Across the Spectrum of Diabetes for Patients with Heart Failure and Reduced Systolic Function

A detailed subgroup analysis has a positive message about this medication.

In the DAPA-HF trial (NEJM JW Cardiol Jan 2020 and N Engl J Med 2019; 381:1995), the sodium–glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduced the risks for cardiovascular death and worsening heart failure and improved symptoms in patients with heart failure and reduced ejection fraction (HFrEF). Although this agent was originally approved as a diabetes treatment, 54% of the 4744 study participants did not have diabetes. Researchers have now performed an exploratory, prespecified, subgroup analysis of this manufacturer-sponsored, randomized, placebo-controlled trial to assess the impact of dapagliflozin according to whether participants had diabetes (history of diabetes or glycated hemoglobin [HgbA_1c] ≥6.5%, n=2139), prediabete…

Reviewing Author

Frederick A. Masoudi, MD, MSPH, FACC, FAHA

Disclosures

Consultant/Advisory BoardBristol Myers Squibb; CPC Clinical Research

Grant/Research SupportNational Heart, Lung, and Blood Institute

Editorial BoardsUpToDate; American College of Cardiology Self-Assessment Program (SAP)

Leadership Positions in Professional SocietiesAmerican College of Cardiology (Chair, Innovations Committee)

Frederick A. Masoudi, MD, MSPH, FACC, FAHA

Disclosures

Consultant/Advisory BoardBristol Myers Squibb; CPC Clinical Research

Grant/Research SupportNational Heart, Lung, and Blood Institute

Editorial BoardsUpToDate; American College of Cardiology Self-Assessment Program (SAP)

Leadership Positions in Professional SocietiesAmerican College of Cardiology (Chair, Innovations Committee)

Dapagliflozin Across the Spectrum of Diabetes for Patients with Heart Failure and Reduced Systolic Function

Topics

Reviewing Author